FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma By Ogkologos - November 13, 2025 369 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AQUILA study Source RELATED ARTICLESMORE FROM AUTHOR Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab MOST POPULAR Identification of Potential Biomarkers for Clinical Benefit Following Dual Neoadjuvant Anti-HER2... May 8, 2021 Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 Women in science: Cancer research pioneers – part 2 January 25, 2023 Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors April 7, 2022 Load more HOT NEWS What to Know When Searching for Cancer Information Online: An Expert... Hospital’s Team Of “Dog-Tors” Helps Sick Kids Feel Less Scared Of... Pembrolizumab Approved for Some Patients with Advanced Esophageal Cancer EMA Recommends Extension of Therapeutic Indications for Durvalumab
